Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $89 from $84 and keeps a Hold rating on the shares. The firm noted Edwards hosted its annual investor day, where the company gave its initial guidance for 2026 and provided updates on its broad pipeline. We believe that the company set guidance that is, at a minimum, achievable.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $96 from $95 at Wells Fargo
- Edwards Lifesciences price target raised to $103 from $100 at BTIG
- Edwards Lifesciences: Strategic Initiatives and Promising Developments Drive Raised Price Target
- Edwards Lifesciences: A Strong Growth Opportunity in Medtech with Expanding Market Potential and Robust Product Portfolio
- Edwards Lifesciences backs FY25 EPS view $2.56-$2.62, consensus $2.59